Sign in
CompletedNo phase

Surgical Implantation of TRAnscatheter vaLve in Native Mitral Annular Calcification (SITRAL) Study

Key facts

Who runs it
Baylor Research Institute
Where
Baltimore, Charlottesville, Houston, Indianapolis, Plano, and Wynnewood, United StatesSee the 6 sites
Trial code
Status
Completed
People taking part
25 people enrolled
Started
4 Nov 2016
Ended
29 Nov 2023
Type of study
Interventional
Treatments tested
  • Mitral Valve Replacement (MVR) with Sapien3
Record updated
24 February 2025

Who can take part

Age
22 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Subject has severe native mitral annular calcification associated with mitral stenosis and/or regurgitation. Qualifying echo must be within 60 days of the date of the procedure
  • Subject has a clinical indication for mitral valve replacement, as demonstrated by reported New York Heart Association (NYHA) Functional Class II or greater
  • The subject is at least 22 years old
  • The Heart Team agrees that the subject is high risk or inoperable for surgical mitral valve repair or replacement (MVR), based on a conclusion that the probability of death or serious, irreversible morbidity exceeds the probability of meaningful improvement. The following concomitant procedures, are allowed: Maze, Tricuspid Valve Procedures (TVP), and Atrial Fibrillation (AF) ablation, coronary artery bypass grafting and septal myectomy
  • The study subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board (IRB) of the respective clinical site
  • The study subject agrees to comply with all required post-procedure follow-up visits

Who cannot take part

  • Evidence of an acute myocardial infarction (MI) ≤ 30 days before the intended treatment [defined as: Q wave MI, or non-Q wave MI with total creatine kinase (CK) elevation of creatine kinase-myocardial band (CK-MB) ≥ twice normal in the presence of myocardial band (MB) elevation and/or troponin level elevation (WHO definition)]
  • Any therapeutic invasive cardiac procedure resulting in a permanent implant that is performed within 30 days of the index procedure (unless part of planned strategy for treatment of concomitant coronary artery disease)
  • Hemodynamic or respiratory instability requiring vasoactive medications, mechanical ventilation at time of procedure
  • Need for emergency surgery for any reason
  • Active upper gastrointestinal (GI) bleeding within 3 months prior to procedure without treatment or 30 days prior to procedure with definitive treatment
  • A known contraindication or hypersensitivity to all anticoagulation regimens, or inability to be maintained on oral anticoagulant following the study procedure
  • End stage renal disease requiring dialysis
  • Clinically (by neurologist) or neuroimaging confirmed stroke or transient ischemic attack (TIA) within 30 days of the procedure
  • Leukopenia (white blood cell count < 2000 cell/mL), acute anemia (hemoglobin < 8 g/dL), or thrombocytopenia (platelet count < 50,000 cell/mL)
  • Severe left ventricular dysfunction with Left Ventricular Ejection Fraction (LVEF) < 30%
  • Severe right ventricular dysfunction
  • Pregnancy, lactation, or planning to become pregnant
  • Echocardiographic evidence of left ventricular mass, thrombus, or concerns of active infective endocarditis
  • Estimated life expectancy < 12 months

Where in United States

  • MHRI MarylandBaltimore, United States
  • University of VirginiaCharlottesville, United States
  • Baylor College of MedicineHouston, United States
  • St. Vincent Heart CenterIndianapolis, United States
  • The Heart Hospital Baylor PlanoPlano, United States
  • Lankenau Institute for Medical ResearchWynnewood, United States

About the trial

What the trial wants to find out

The purpose of this study is to establish the safety and feasibility of the Edwards SAPIEN 3 valve in subjects with mitral annular calcification (MAC) associated with mitral stenosis (MS) and/or mitral regurgitation who are at high-risk for mitral valve surgery or deemed inoperable due to the extent of calcification.

The group in the trial

  • Mitral Valve Replacement (MVR) with Sapien3Treatment being tested

    subjects with surgical MVR with Sapien3

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
24 February 2025